oseltamivir
Trade name: tamiflu
Approved
Oct 27, 1999
Oseltamivir phosphate is an ethyl ester prodrug requiring ester hydrolysis for conversion to the active form, oseltamivir carboxylate. Oseltamivir carboxylate is an inhibitor of influenza virus neuraminidase affecting release of viral particles. Oseltamivir is a well tolerated orally active neuraminidase inhibitor which significantly reduces the duration of symptomatic illness and hastens the return to normal levels of activity when initiated promptly in patients with naturally acquired influenza. — NCATS
Clinical trial activity
139 trials · 137 clinical orgs · 32 marketing orgs
Earliest trial started Oct 1, 2001 (NCT02617784)
Timeline
2000s
2010s
- Aug 3, 2016
Natco Pharma — Marketing Organization
- Feb 24, 2017
Zydus Discovery DMCC — Marketing Organization
- Feb 24, 2017
Nesher Pharms — Marketing Organization
- May 17, 2017
Amneal Pharmaceuticals — Marketing Organization
- Sep 14, 2017
Macleods Pharmaceuticals, Ltd — Marketing Organization
- Sep 14, 2017
Neogen — Marketing Organization
- Oct 31, 2017
Alvogen — Marketing Organization
- Jan 9, 2018
Lupin — Marketing Organization
- Feb 23, 2018
Hetero Labs Ltd — Marketing Organization
- Jun 8, 2018
Strides Pharma Science — Marketing Organization
- Feb 27, 2019
Teva — Marketing Organization
- Jun 24, 2019
Alembic — Marketing Organization
2020s
- Mar 4, 2020
Sunshine Lake Pharma Co., Ltd. — Marketing Organization
- May 20, 2020
MSN Laboratories — Marketing Organization
- May 27, 2020
Ajanta Pharma Ltd — Marketing Organization
- Jan 21, 2021
Rising Pharmaceuticals — Marketing Organization
- Jan 21, 2021
Mylan — Marketing Organization
- Aug 30, 2021
Aptapharma Inc — Marketing Organization
- Oct 1, 2021
Epic Pharma Llc — Marketing Organization
- Feb 28, 2022
Leading Pharma Llc — Marketing Organization
- Jul 25, 2022
Accord Research — Marketing Organization
- Oct 3, 2023
Invagen Pharms — Marketing Organization
- Nov 24, 2023
Hainan Poly Pharm — Marketing Organization
- Nov 24, 2023
ZHEJIANG POLY PHARM — Marketing Organization
- May 1, 2024
Laurus Labs Ltd — Marketing Organization
- May 10, 2024
Aurobindo Pharma — Marketing Organization
- Jul 2, 2024
Oryza — Marketing Organization
- Oct 30, 2024
NANJING DAOQUN — Marketing Organization
- Dec 3, 2024
Cediprof Inc — Marketing Organization
- Mar 3, 2025
Jubilant Innovation Ltd. — Marketing Organization
- Jul 9, 2025
Shandong Lanjin Pharmaceuticals Co.,Ltd — Marketing Organization
Indications
Approved for
Studied for
- Atrial Fibrillation · Phase 4
- Atrial Flutter · Phase 4
- Coronavirus Infections · Phase 4
- COVID-19 · Phase 3
- Critical Illness · Phase 2
- Drug Interactions · Phase 1
- Drug Therapy, Combination · Phase 4
- Healthy Volunteers · Phase 2
- Infections · Phase 1
- Influenza A virus · Phase 3
- Influenza B virus · Phase 3
- Influenza in Birds · Phase 2
- Kidney Failure, Chronic · Phase 1
- Lung Diseases · Phase 1
- Lymphoma · Phase 2
- Metabolic Diseases · Phase 4
- Obesity · Phase 1/Phase 2
- Pneumonia · Phase 4
- Pregnancy · Phase 1
- Pulmonary Disease, Chronic Obstructive · Phase 4
- Purpura, Thrombocytopenic, Idiopathic · Phase 3
- Respiratory Tract Infections · Phase 4
- SARS-CoV-2 · Phase 4
- ST Elevation Myocardial Infarction · Phase 4
- Therapeutic Equivalency · Phase 1
- Thrombocytopenia · Phase 2
- Virus Diseases · Phase 2
- Virus Shedding · Phase 3
Mechanism of action
- NeuraminidaseINHIBITOR
Neuraminidase inhibitor
- NeuraminidaseINHIBITOR
Neuraminidase inhibitor
Approval history
- approvedPriority reviewOct 27, 1999
Chemistry & pharmacology
SMILES
CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1- Mol. weight
- 312.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1229 ↗
- WikipediaOseltamivir ↗
- NCATSK6106LV5Q8 ↗
- ChEMBLCHEMBL1200340 ↗
Also known as
- 1-cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3r-(3alpha,4beta,5alpha))-
- 1-cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3r-(3alpha,4beta,5alpha))-
- ebilfumin
- ebilfumin
- ebilfumin
- ebilfumin
- ebilfumin
- ebilfumin
- ethyl (3r,4r,5s)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate
- ethyl (3r,4r,5s)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate
- oseltamivir
- oseltamivir
- oseltamivir
- oseltamivir
- oseltamivir
- oseltamivir
- oseltamivir
- oseltamivir
- oseltamivir
- (−)-oseltamivir
- (−)-oseltamivir
- oséltamivir
- oséltamivir
- oseltamivir carboxylate
- oseltamivir carboxylate
- oseltamivir phosphate
- oseltamivir phosphate
- oseltamivir phosphate
- oseltamivir phosphate
- oseltamivir phosphate
- oseltamivirum
- oseltamivirum
- ro-640796
- ro-640796
- ro-640796002
- ro-640796002
- ro-64-0796-002
- ro-64-0796-002
- tamiflu
- tamiflu
- tamiflu
- tamiflu
- tamvir
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07229807 | Phase 3 | Nov 30, 2025 | Guangdong Raynovent Biotech Co., Ltd |
| NCT07236814 | Phase 3 | Nov 24, 2025 | Capital Medical University |
| NCT07095257 | Phase 3 | Oct 13, 2025 | Hangzhou Zenshine Pharmaceuticals Co., Ltd. |
| NCT07113392 | Phase 3 | Aug 1, 2025 | Government of China |
| NCT06762587 | N/A | Jan 5, 2025 | Capital Medical University, Chinese Academy of Medical Sciences, Peking University |
| NCT06774859 | Phase 3 | Oct 27, 2024 | Roche |
| NCT06507813 | Phase 3 | Jun 28, 2024 | Government of China |
| NCT06462417 | N/A | Jun 20, 2024 | Huazhong University of Science and Technology, National Natural Science Foundation of China |
| NCT06057103 | Phase 1 | Aug 25, 2023 | Hangzhou Zenshine Pharmaceuticals Co., Ltd. |
| NCT05818124 | Phase 1 | Aug 21, 2023 | Merck |
| NCT05789342 | Phase 1 | Feb 15, 2023 | Peking University, Qingfeng Pharmaceutical Group |
| NCT05648448 | Phase 2 | Dec 22, 2022 | University of Oxford |
| NCT05170009 | Phase 2/Phase 3 (Phase 3) | Apr 22, 2022 | Cornell University, Genentech |
| NCT05083325 | Phase 1 | Oct 8, 2021 | Grunenthal |
| NCT05012189 | Phase 4 | Aug 6, 2021 | Brown University, Case Western Reserve University, Genentech, Insight Therapeutics, LLC |
| NCT05297968 | Phase 1 | May 13, 2021 | Qingdao University |
| NCT04712539 | Phase 2 | May 1, 2021 | University of Texas at Houston |
| NCT05008679 | N/A | Feb 25, 2021 | Huazhong University of Science and Technology |
| NCT04683406 | Phase 3 | Dec 31, 2020 | Guangdong Raynovent Biotech Co., Ltd |
| NCT05108051 | Phase 1 | Nov 19, 2020 | Guangdong Raynovent Biotech Co., Ltd |
Organizations
Research & Development (137)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 30 | 18 | 5 | 2001 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 9 | 7 | 4 | 2006 |
| University of Oxford | Academic/Hospital | 8 | 4 | 4 | 2006 |
| Capital Medical University | Academic/Hospital | 7 | 6 | 4 | 2009 |
| GlaxoSmithKline | For profit | 6 | 5 | 3 | 2007 |
| Huazhong University of Science and Technology | Academic/Hospital | 5 | 5 | 3 | 2020 |
| Mahidol University | Academic/Hospital | 5 | 1 | 3 | 2006 |
| Peking University | Academic/Hospital | 5 | 1 | 4 | 2014 |
| Centers for Disease Control and Prevention (CDC) | Government | 4 | 1 | 3 | 2008 |
| Genentech | For profit | 4 | 2 | 3 | 2013 |
| Johnson and Johnson | For profit | 4 | 4 | 2 | 2014 |
| Chinese University of Hong Kong | Academic/Hospital | 3 | 3 | 2 | 2009 |
| Government of China | Government | 3 | 2 | 1 | 2019 |
| Guangdong Raynovent Biotech Co., Ltd | For profit | 3 | 3 | 2 | 2020 |
| Guangzhou Medical University | Academic/Hospital | 3 | 2 | 2 | 2012 |
| MedImmune | For profit | 3 | 3 | 1 | 2015 |
| National Institutes of Health (NIH) | Government | 3 | 0 | 3 | 2005 |
| The University of Hong Kong | Academic/Hospital | 3 | 3 | 3 | 2009 |
| Anhui Medical University | Academic/Hospital | 2 | 0 | 2 | 2016 |
| BioCryst | For profit | 2 | 2 | 2 | 2007 |
Marketing (42)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Accord Research | For profit | MKTG | Jul 25, 2022 |
| Ajanta Pharma Ltd | For profit | MKTG | May 27, 2020 |
| Alembic | For profit | SYN | Jun 24, 2019 |
| Alembic | For profit | MKTG | Jun 24, 2019 |
| Alvogen | For profit | SYN | Oct 31, 2017 |
| Alvogen | For profit | MKTG | Oct 31, 2017 |
| Amneal Pharmaceuticals | For profit | MKTG | May 17, 2017 |
| Amneal Pharmaceuticals | For profit | SYN | Feb 27, 2018 |
| Aptapharma Inc | For profit | MKTG | Aug 30, 2021 |
| Aurobindo Pharma | For profit | MKTG | May 10, 2024 |
| Cediprof Inc | For profit | MKTG | Dec 3, 2024 |
| Epic Pharma Llc | For profit | MKTG | Oct 1, 2021 |
| Hainan Poly Pharm | For profit | MKTG | Nov 24, 2023 |
| Hetero Labs Ltd | For profit | SYN | Mar 28, 2022 |
| Hetero Labs Ltd | For profit | MKTG | Feb 23, 2018 |
| Invagen Pharms | For profit | MKTG | Oct 3, 2023 |
| Jubilant Innovation Ltd. | For profit | MKTG | Mar 3, 2025 |
| Laurus Labs Ltd | For profit | MKTG | May 1, 2024 |
| Leading Pharma Llc | For profit | MKTG | Feb 28, 2022 |
| Leading Pharma Llc | For profit | SYN | Feb 28, 2022 |
| Lupin | For profit | MKTG | Jan 9, 2018 |
| Lupin | For profit | SYN | Jan 9, 2018 |
| MSN Laboratories | For profit | MKTG | May 20, 2020 |
| Macleods Pharmaceuticals, Ltd | For profit | MKTG | Sep 14, 2017 |
| Mylan | For profit | MKTG | Jan 21, 2021 |
| NANJING DAOQUN | For profit | MKTG | Oct 30, 2024 |
| Natco Pharma | For profit | SYN | Aug 3, 2016 |
| Natco Pharma | For profit | MKTG | Aug 3, 2016 |
| Neogen | For profit | MKTG | Sep 14, 2017 |
| Nesher Pharms | For profit | MKTG | Feb 24, 2017 |
| Oryza | For profit | MKTG | Jul 2, 2024 |
| Rising Pharmaceuticals | For profit | SYN | Jan 21, 2021 |
| Rising Pharmaceuticals | For profit | MKTG | Jan 21, 2021 |
| Roche | For profit | NDA | Oct 27, 1999 |
| Roche | For profit | SYN | Oct 27, 1999 |
| Shandong Lanjin Pharmaceuticals Co.,Ltd | For profit | MKTG | Jul 9, 2025 |
| Strides Pharma Science | For profit | MKTG | Jun 8, 2018 |
| Sunshine Lake Pharma Co., Ltd. | For profit | MKTG | Mar 4, 2020 |
| Sunshine Lake Pharma Co., Ltd. | For profit | SYN | Mar 4, 2020 |
| Teva | For profit | MKTG | Feb 27, 2019 |
| ZHEJIANG POLY PHARM | For profit | MKTG | Nov 24, 2023 |
| Zydus Discovery DMCC | For profit | MKTG | Feb 24, 2017 |